Clinical Trial Update: Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

Phase 2 open-label extension study assessing tolerability of combining BCI-024 with BCI-049 in adults with major depressive disorder; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• BCI-024
• BCI-049

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2013-12-17